view one cleaner de-risk growth stori current biotech
reshap depression-treat paradigm particularli given zulresso
approv next-gen oral phase /mdd doctor
check suggest sale opportun could like consensu
initi buy price target ahead pivot mdd data
move host depress panel boston day
develop novel treatment disord includ zulresso post-
partum depress major depress disord mdd
recov low late decemb amid zulresso
approv posit phase data next-gen oral although
zulresso show unpreced benefit eras depress within day mani
patient think could linchpin compani depress franchis
valuat target us patient annual mdd
addit oral safer could suitabl home use
rem restrict vs hospit zulresso see buyer step ahead
import phase mdd data upsid data open
opportun bear say slow launch zulresso mdd studi binari
risk takeout
check suggest could opportun investor debat center
peak sale drug account valuat
estim iv zulresso peak sale could reach oral could
reach vs consensu doctor
upbeat envis payor hurdl one doc will prescrib
anyon cover insur conceptu net price mdd pt
us mdd pt pt ssri annual preced
includ lundbeck lexapro narrow label mdd anxieti
gsk wellbutrin lundbeck celexa mdd earli
impli least market cymbalta mdd
neuropath pain fibromyalgia ssri alreadi gone gener
investor rule eventu look recent neurolog comp
analysi histor suggest pharma will pay peak sale
novel neurolog drug valuat also note
nv buy-out avx reflect pharma desir acquir innov
zulresso pharma spearhead blockbust ssri launch
lundbeck gsk would view easi tuck-in
neurolog salesforc given duodopa mitsubishi given neuroderm
given synergi even like phase mdd data large-scal
mega appetit improv pushback recent mostli gene
therapy/oncolog stock expens alreadi neuro smid still stand-alone
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
base case base sum-of-the-
part sotp analysi brexanolon
mdd addit mdd
account label expans opportun
includ mainten therapi retreat therapi mdd
comorbid insomnia indic build
revenu cash flow stream
probability-adjust dcf think repres
valuat
upsid scenario consid slightli higher
peak sale estim zulresso assum higher
probabl success versu base case
mdd indic addit ascrib valu
earlier-stag phase i/ii program
parkinson huntington
downsid scenario incorpor lower
peak sale zulresso lower probabl success
ppd/mdd program downsid scenario
assum potenti safeti issu aris loss
conscious syncop inabl
meet primari endpoint studi
scenario zulresso launch could soft
could gener unfavor side effect properti
delay prevent approv limit commerci opportun
result unfavor outcom clinic reject
addit ascrib valu earlier-stag
reshap depression-treat paradigm
particularli zulresso next-gen oral
ppd/mdd think path least resist
stock higher sinc doctor note next-
gen oral compel use case commerci
help affirm view peak sale could
reach time
compani depress franchis valuat target
us patient annual mdd
time estim ww revenu could reach
linchpin
vs con
analysi histor transact suggest
pharma will pay peak sale lead neurolog
drug suggest valuat peak sale
peak sale
issu interim final rule control zulresso
within day approv
june zulresso commerci launch
phase cohort data huntington
phase cohort data essenti tremor
phase mad data healthi
final ema file strategi zulresso
obtain feedback fda sleep
start phase mdd mainten studi keep
phase data mdd mountain
phase polysomnographi data mdd
co-morbid insomnia rainforest
phase open-label data retreat
pleas see import disclosur inform page report
financi summari market data
gener estim pro-forma cash balanc share outstand account feb
gener estim pro-forma cash balanc share outstand account feb
estim valuat
pleas see import disclosur inform page report
pictur view one cleaner de-risk growth stori biotech
current two novel depress drug enter market think could
gener cumul peak sale reshap treatment paradigm
depress particularli iv zulresso approv postpartum depress
next-gen oral gener posit phase data
phase data major depress disord mdd key
catalyst specif zulresso drug approv antidepress
ssri current use off-label like first novel mechan
action year approv broad mdd note esketamin recent approv
mdd popul subgroup call treatment-resist depress see
first-mov advantag zulresso competitor may least year
behind mdd
clear zulresso core part thesi repres estim
valuat import aspect pave path
expect linchpin compani depress franchis target
us patient annual mdd popul addit
taken oral safer could allow home use vs hospit zulresso sinc
expect rem restrict
term stock perform stock low
share late dec driven posit phase data jan
improv biotech tape year ibb also recov low
ytd acknowledg stock mostli range-bound throughout
except possibl investor debat around zulresso
launch expect slow somewhat limit market opportun
rel lack pipelin catalyst look ahead increas activ
favor macro environ help improv smid-cap sentiment could see
stock continu climb higher middl histor
trade rang toward upper end compani schedul report
phase data mdd posit suggest potenti upsid
data mix though expect stock could move closer
downsid scenario assum probabl success mdd
fda agre allow file nda base three pivot studi two
complet alreadi mdd scenario third studi
mdd mix believ could leverag least one three label expans
mdd studi back-up pivot studi data well
vision rethink depress treat compani
report posit placebo-control phase ii/iii data ppd/mdd could complet
anoth placebo-control phase mdd studi rel
high probabl success view key near-term catalyst phase mdd
data remain mdd studi enhanc revenu
opportun establish long-term safeti posit result would enabl
garner differenti robust label nonetheless exist data look
compel alreadi favor efficaci ssri make us believ
potenti disrupt treatment paradigm ppd/mdd real especi sinc
pleas see import disclosur inform page report
avail acut psychiatr treatment resolv symptom major
sale possibl base doc convers see insid detail
believ revenu opportun zulresso could total
mdd antidepress like zoloft prozac long
mainstay therapi depress notori take sever weeks/month
allevi symptom ineffect mani patient begin chronic
treatment doctor agre zulresso provid relief within hour
virtual eras symptom within day patient week mdd
addit work irrespect whether patient on/off antidepress
refer cymbalta antidepress gener revenu
approv mdd neuropath pain fibromyalgia despit face gener
competit drug eventu reach peak
addit wellbutrin celexa antidepress fda label sole mdd
gener peak sale earli
conceptu sale net price mdd patient patient
diagnos annual us patient antidepress year
valuat framework although expect gener high current trade
market cap still see upsid downsid current price level
pt base sotp analysi consid zulresso brexanolon
probability-adjust program mdd upsid scenario
pt primarili consid higher po mdd ascrib valu early-
stage pipelin bipolar depress downsid scenario
consid lower po mdd exclud early-stag pipelin
think path least resist stock higher sinc doctor
spoke support view phase mdd data posit
compel use case commerci
investor rule eventu analysi histor transact
suggest pharma will pay peak sale neurolog compani lead
product appli multipl estim peak sale would peg
valuat peak sale would impli valuat
 bull case acquisit justifi pharma believ
reach peak sale leverag given brexanolon
drug approv specif could eventu transform
mdd treatment paradigm nv recent acquisit avx suggest pharma
still will acquir innov product zulresso pharma
tradit spearhead ssri drug launch could good tuck-in
program neurolog salesforc may want asset given duodopa
could want tuck-in neuro synergi mitsubishi bought neuroderm takeda/shir
could also find synergi becom even like phase mdd
data posit larger-scal mega appetit improv
pleas see import disclosur inform page report
price/bas case base case base sotp analysi
zulresso brexanolon mdd addit mdd
account label expans opportun includ mainten therapi
retreat therapi mdd comorbid insomnia indic build
revenu cash flow stream probability-adjust dcf
believ repres valuat
upsid scenario upsid scenario consid slightli higher peak sale
estim zulresso assum higher probabl success versu base case
mdd indic addit ascrib valu earlier-
stage phase i/ii program bipolar broad insomnia essenti
tremor seizur parkinson huntington
downsid scenario downsid scenario incorpor lower peak sale
zulresso lower probabl success ppd/mdd program
downsid scenario assum safeti issu aris loss conscious syncop
meet primari endpoint studi
zulresso launch could soft could gener unfavor
side effect properti delay prevent approv limit commerci opportun
result unfavor outcom clinic reject letter limit patient
uptak minim sale traction addit ascrib valu earlier-stag
pleas see import disclosur inform page report
pleas see import disclosur inform page report
question debat
doctor think zulresso brexanolon
convers doctor suggest brexanolon launch could soft
could prove real winner doctor gener sound balanc
zulresso upbeat current treat around
mdd patient envis zulresso limit sever patient
popul despit drug approv wherea uptak
like much stronger given oral conveni better safeti profil nonetheless
drug confer advantag gener srri latter gener take
week show efficaci vs earli day zulresso
ineffect mani patient begin
doctor think zulresso brexanolon sound good paper see
hurdl launch
gener background current treatment doctor use psychotherapi
therapi patient sinc talk therapi resolv symptom
within hour week doctor emphas psychotherapi safest
method treatment
two-third patient psychotherapi move antidepress use off-
label common zoloft celexa lexapro secondarili
prozac luvox paxil drug compar efficaci
patient reluct use medic especi mother nurs
sever includ mild moder sever
first drug approv unequivoc effect symptom resolv
within hour rapid onset action provid better option ssri
use label gener speak appear safe loss consciousness/
con rem restrict requir patient hospit monitor
continu infus done home babi
would need accompani mother breastfe make logist challeng
may caus loss conscious dizzi sedat given brexanolon
price tag payor could put zulresso first tier payor discuss inde
way could requir doctor treat patient cheap gener ssri possibl
multipl ssri start brexanolon brexanolon hidden cost includ
payment nurs hospit stay hospit overbook sometim
drug feasibl patient
market implic zulresso doctor envis limit zulresso sever
patient popul one doctor plan treat new patient
psychotherapi antidepress brexanolon anoth would
prescrib sever patient repres patient
one doctor would prescrib oral ppd/mdd patient cover
insur
gener background current treatment mdd doctor also use
psychotherapi patient will take ssri patient
pleas see import disclosur inform page report
repres paradigm shift antidepress take week show
efficaci oral alway win iv practic drug like
escap rem taken home rem drug never well phase
ii mdd phase data look promis even though patient take
night make unclear whether drug absolut caus loss
conscious experi residu effects/impair next day
doctor colleagu suggest physician feel comfort prescrib
brexanolon
con would like cannib brexanolon sale
approv payor may requir patient take srri first mdd
three dozen gener ssri approv alway cheaper
could still compet esketamin later line therapi
market implic doctor agre uptak
like strong sinc srri gener take week exhibit efficaci vs earli
day one doctor would prescrib mdd
patient begin prescrib pattern increas time feedback
patient doctor valid safeti real world set anoth
doctor would prescrib anyon cover insur even though
mdd market crowd doctor believ confer advantag ssri
would definit prescrib approv
also doctor agre ganaxolon need watch
oral ganaxolon come market doctor believ ganaxolon brexanolon
could share market especi sinc ganaxolon
show loss conscious doctor view competit dynam akin
multipl ssri avail one doctor particularli interest ganaxolon
short iv bolu hour oral dose day method would enabl administr
outpati set serv sever popul well
would view posit phase
believ phase data look larg similar prior phase ii data
although possibl larger studi could caus efficaci wane
slightli phase studi mountain patient take treatment
daili follow week design larg similar phase ii
except evalu two dose placebo versu phase
ii among small nuanc expect show loss conscious
syncop faint
patient inclus criteria adult whose mdd symptom present
least four week
dose low dose high dose
primari endpoint day chang depress score
secondari endpoint week day chang score cgi
depress score instanc
pleas see import disclosur inform page report
extens phase plan add extens trial mountain studi
follow patient complet
expect phase mdd data
score rapid onset effect day day efficaci maintain
trend lower week would plu clear dose- respons along
dose separ placebo across time point especi within week day
high dose show stat-sig mean reduct point vs point
placebo point pbo-adj delta stat-sig pbo-adjust reduct
point week rang would compar prior phase ii data
remiss rate score normal statu day secondarili
week placebo-adjust remiss rate rang stat-sig rang
would compar prior phase ii data day week unadjust
basi would like see remiss rate fall around vs
placebo
gener efficaci trend clear separ compar placebo earli
hour statist signific benefit placebo depress score
response/ remiss rate clear dose respons
safeti report syncop faint loss conscious sae
death would like see overal balanc placebo
specif instanc dizzi nausea around vs placebo sedat
around line placebo
could sale spoke doctor look
believ ww revenu could reach vs con
driven primarili vast mdd patient popul individu
us alon sum-of-the-part sotp model consid broad
mdd popul well variou mdd expans indic target
label expans studi evalu mdd patient also suffer
insomnia repres mdd patient mainten therapi keep
patient symptom-fre post remiss retreat therapi patient
whose mdd symptom reoccur also assum zulresso brexanolon gener
peak sale
model deriv sale mdd
label expans opportun within mdd assum
start price us eu/japan respect
probability-adjust basi sotp valuat depress franchis
result split evenli brexanolon
mdd mdd extens indic result
price target
note price target ascrib valu earlier-stag program
bipolar depress broad insomnia essenti
tremor could repres multi-billion dollar peak sale opportun
pleas see import disclosur inform page report
view posit phase i/ii data program would provid
upsid view
peak sale estim support channel check
depress doctor doctor posit mdd
one doctor would hypothet prescrib mdd patient without
one doctor note mdd market crowd approv gener ssri
specul payor repres hurdl potenti uptak
like price much higher gener ssri howev would still prescrib
anyon cover insur
anoth doctor envis prescrib patient start
prescrib usag potenti increas time feedback patient
doctor valid safeti real world set
doctor note moderate/sever mdd repres around two-third mdd
patient sever said anoth way mdd patient
sever
mdd model assum peak penetr us japan
eu outer year
note moderate-to-sever popul peak penetr mdd
patient target penetr suggest doctor
addit look preced drug launch antidepress ssri
mani success stori gener peak sale
go gener
count least eight brand antidepress reach blockbust statu prior
generic drug manag gener least peak sale
point
brand depress drug market worth quickli lost
third valu decad later pharma compani unabl introduc novel
drug differenti gener formul
note follow data point support peak sale estim
mdd preval gener increas sinc due grow
popul lundbeck lexapro manag gener ww sale
despit receiv rel narrow indic mdd anxieti disord gsk
wellbutrin lundbeck celexa gener peak sale sole
mdd market even though wellbutrin small risk seizur celexa caus
arrhythmia higher dose cymbalta gener peak sale across
variou indic presenc variou gener ssri fact cymbalta
sale mdd neuropath pain fibromyalgia drug
receiv label expans anxieti musculoskelet pain
comparison exclud mdd expans studi opportun
could arriv peak sale estim closer gener
mdd think assumpt reason base doctor convers
suggest transform acut treatment vs chronic therapi
antidepress wide prescrib given all-or option rapid onset action day
vs sever week ssri favor risk/benefit profil rem restrict
anticip due loss conscious faint help open mdd
pleas see import disclosur inform page report
market opportun sinc mani mdd patient current undergo
bottom line assum phase studi show posit efficaci clean
safeti drug approv mdd pdd gener
cumul peak sale moreov addit revenu could deriv
drug receiv differenti label predic whether show
posit phase data three mdd studi retreat therapi
comorbid insomnia mainten
exhibit sale label comparison antidepress esketamin
pleas see import disclosur inform page report
 mddsale billion estim sale antidepress vs expans studi mdd year peak salescompanybrandedgenerictypeind approv sale yearblackbox chronic tx note safeti issu angelini etcnorem restrictiongskwellbutrinbupropionndri risk seizureslundbeck/ arythmia higher dosesllyprozacfluoxetinessrimdd ocd bn pd trd children/teenagersgskpaxilparoxetinessrimdd ocd pd ptsd sad side effectspfezoloftsertralinessrimdd ocd pd ptsd sad forestlexaproescitalopramssrimdd children/teenagerspfeeffexorvenlafaxinesnrimdd gad sad reduct hepatic/ren llycymbaltaduloxetinesnrimdd gad dpnp fm ad rem expect combin antidepress combin olanzapin major depress disord mdd panic disord pd obsessive-compuls disord ocd post-traumat stress disord ptsd social anxieti disord sad premenstru dysphor disord pmdd bulimia nervosa cn treatment-resist depress trd gener anexieti disord gad diabet peripher neuropath pain dpnp fibromyalgia fm chronic musculoskelet pain equiti research
type valuat might fetch scenario
look neurolog comp
past year recent april variou media outlet
suggest could acquisit candid presum pharma
compani exist neurolog salesforc howev ceo subtli dampen
 specul say recent confer call on-line public
mission becom lead independ compani addit march
explicitli state intent ceo remain independ compani
creat sharehold valu
said investor rule though main thesi
bear case somewhat expens alreadi market cap recent
neuro comp suggest big pharma interest sub acquisit
unwil gambl major drug launch sinc recent neuro drug launch
slow nuplazid sale teva austedo
particular gocovri also neuro smid still
stand-alone aldr gwph etc nearli
antidepress gone gener big pharma may longer depress
sale forc pharma may prone in-licens neuro compound
acquir
bull case acquisit justifi big pharma believ
could reach peak sale time leverag given
brexanolon drug approv specif could
eventu transform mdd treatment paradigm nv recent acquisit
avx suggest big pharma still will acquir innov product big
pharma tradit spearhead major ssri drug launch past
would repres good tuck-in program neurolog salesforc
may want asset given duodopa could want tuck-in neuro synergi
mitsubishi bought neuroderm takeda/shir could also find synergi
 becom even like phase mdd data posit larger-
scale mega appetit improv
analysi histor transact suggest pharma will pay
peak sale neurolog compani lead product appli multipl
estim peak sale would peg valuat peak
sale would impli valuat histor multipl rang
celg/recepto lly/colucid otsuka/avnr
nvs/avx comp analysi support sotp wipe
expens across variou dcf
pleas see import disclosur inform page report
pleas see import disclosur inform page report
sumitomo pharmasepracor latuda lurasidon schizophrenia neurologyphas xn/aall nuvigil modafinil excess sleepinesscn xall pharmaceuticalslevadexacut migrain x-all fremanezumab migrain cgrp neurologyphas xn/aall episodesneurologyphas xn/aall duchenn muscular dystrophneuromuscular phase xn/aall xn/aall associ w/ huntington diseaseneurologynda xn/aall droxidopa neurogen orthostat hypotens noh neurolog xn/aall sclerosi ulcer colitisneurologygastrointestinalphas xn/aall xn/aall pharmaceuticalsxenoporthorizantmoderate-to-sever restless leg xn/aall episodesneurologyphas xn/aall lillycolucidlasmiditanmigraineneurologyphas xn/aall diseaseneurologyphas xn/aall npc-rare xn/aall gene therapi neurologyphas xn/aall stock cash mix amount estim base initi announc sale refer franchis core product deal diversifi co recent stock termin feeslead stage time deal deal value/ salestakeout forward p/edat announcedacquirortargetprimari assetprimari indicationdiseas categoryd valu ltm sale sale estimate deal value/ ltm sale exhibit neurolog compani acquir sale novel neurolog drug
exhibit dcf scenario expens strip
pleas see import disclosur inform page report
cephalonmap multiplem scenario expens strip chang assumpt depress zulresso major depress disord mdd mdd- mdd maintenance- mdd retreatment- mdd comorbid insomnia- total mileston shionogi good tax a- stock option expense- capex- work capital- discount npv programspospeak revenuetermin growth postpartum depress discount postpartum depress blend major depress disord probabl adjust mdd share count mdd add mdd comorbid minu debt- market price per select event sinc ipo
jefferi compani report factset analyz april
pleas see import disclosur inform page report
juli ipo brxphase ii top-line srse datamay brxphase i/ii srse datajun brxopen-label data sep brxphase essentialtremor data oct phase healthiesjune-juli brxphase ii data ema validatesbrxphas srse studyfeb iia open-label mdd datasep brxphase srse studyfail posit phase brxdata dec posit phase ii datajan i/ii sleep disorderdatafeb speculationheighten deni rumorsapr brxnda filingjun fdaagre mdd/ brxadcom panel pdufa extensionjan datamar brxapprov equiti research
primari debat peak sale whether phase mdd data posit
approv lead drug brexanolon zulresso essenti de-risk novel mechan class pave way next-gen oral latter
could peak sale potenti ppd/mdd behind addit assets/program current phase i/ii neuropsychiatri neurolog
compani trailblaz depress treatment antidepress use chronic therapi zulresso establish acut therapi
consist establish zulresso iv oral efficaci larg random placebo-control program mdd drug similar
mechan achiev clinic meaning rapid separ placebo depress symptom liter within day administr efficaci maintain
durabl day
expect slow zulresso launch primari thesi repres estim valuat
zulresso doctor say first drug approv unequivoc effect symptom resolv within hour rapid onset action provid better
option ssri use label appear safe gener loss consciousness/faint seem transient
doctor say repres paradigm shift antidepress take week show efficaci oral alway win iv practic
drug like escap rem taken home rem drug never well
doctor say would prescrib patient anyon cover insur
peak sale net price mdd patient annual us mdd patient patient ssri annual
within mdd build label conduct addit studi could help reshap depress landscap retreat studi patient
relaps mainten studi keep patient symptom-fre studi could underappreci street
preced lundbeck lexapro narrow label mdd anxieti gsk wellbutrin lundbeck celexa mdd earli
suggest least market cymbalta mdd neuropath pain fibromyalgia ssri gone gener
would repres good tuck-in program neurolog salesforc given duodopa mitsubishi given neuroderm given tuck-in synergi
make sens mdd prescrib patient fail ssri drug work irrespect whether patient on/off antidepress
us composit matter com patent expir extens
mani mdd competitor gener antidepress cheap kol compar latter two competitor target differ
popul esketamin recent approv mdd popul subgroup call treatment-resist depress believ direct competitor least
actual diversifi portfolio across depress neuropsychiatri neurolog space sever free call option bipolar depress tremor parkinson
huntington seizur etc posit data program would add upsid stock theoret blockbust indic
pleas see import disclosur inform page report
high expect alreadi expens market cap phase mdd data binari could bias toward downsid
zulresso launch slow initi could establish neg preced compani even guid expect strong momentum compani
need establish center excel garner support payor rem restrict limit sale potenti consensu model peak sale drug
doctor think zulresso brexanolon sound good paper see hurdl launch rem loss conscious faint high price
tag includ cost includ hospit stay potenti capac issu bed
doctor note mani patient undergo psychotherapi mani immedi experi benefit requir medic
antidepress patient psychotherapi move medic
doctor note gener mdd treatment alreadi issu
payor may requir patient fail antidepress move limit sale potenti
one instanc loss conscious albeit shock could elimin valu proposit crater stock
valuat heavili weight even drug approv later could still downsid risk peak revenu estim drug
wide expect becom multi-billion dollar blockbust drug
phase mdd studi still risk phase ii may never translat phase data placebo-adjust remiss rate lower phase
assum eventu becom approv ppd/mdd actual number mild/moder diagnos patient could much smaller anticip
precis method establish exact number
name last time major depress drug achiev peak sale
eu file plan still pend
long-term data limited/unclear ppd/mdd patient experi strong clinic effect come gaba-a modul long-term safeti durabl mainten
retreat interv open question
effect mdd appear fade time see phase ii depress graph
shown posit phase ii moderate/sever mdd data report phase data treatment-resist depress trd subset mdd plan meet
fda discuss regulatori strategi broad mdd
buy-out said publicli remain commit lead independ compani
recent neuro comp suggest pharma interest sub acquisit unwil gambl major drug launch
recent neuro drug launch slow nuplazid sale teva austedo particularli gocovri
opex continu grow y/i
pleas see import disclosur inform page report
pleas see import disclosur inform page report
companytickerratingpric targetpricelead drugdrug lead indicationstagemarket cap debt enterpris valu tecfideramultipl zulresso brexanolon postpartum neurocrin ingrezzatard gw epidiolex pediatr acadia nuplazid pimavanserin parkinson diseas biohaven rimegepantacut migrainephas pediatr alder eptinezumabmigrain preventionnda intra-cellular lumateperoneschizophrenianda acorda inbrijaparkinson axsom depressionphas marinu ganaxolonepostpartum depressionphas zynerba syndron fx phase gocovriparkinson diseas aquest sympazan pediatr aptinyx dpn fibromyalgiaphas estim cash debt balanc post feb raisepr equiti research
found massachusett develop portfolio gaba-a nmda
receptor candid treat variou central nervou system disord gaba-a
receptor aim inhibit neurotransmiss calm brain potenti
treat mood movement disord nmda receptor increas signal
nerv cell stabil neural network potenti treat cognit dysfunct
disord dysfunct two system thought caus psychiatr
brexanolon zulresso iv formul lead product brexanolon
zulresso gaba-a receptor modul intend treat postpartum depress
approv fda march zulresso expect launch june
schedul drug
mdd other oral dose next advanc product
candid next-gen gaba-a receptor modul target major
depress disord mdd report posit phase ii mdd data
phase data jan compani expect report phase mdd data
mountain later
also work label expans opportun
mdd co-morbid insomnia mainten therapi keep patient
symptom-fre retreat therapi retak symptom
reoccur studi phase data
addit evalu depress disord bipolar
depress broad sleep disord
tremor seizur parkinson diseas chronic oral dose phase
result suggest similar zulresso next-gen gaba-a receptor
modul design dose chronic oral evalu drug
variou neurolog condit includ essenti tremor certain epileptiform
disord seizur phase essenti tremor data expect
current evalu gaba-a variou formul treat
nmda receptor first nmda product candid compani
evalu drug phase studi patient cognition-rel disord
 neg impact nmda receptor dysfunct indic involv nmda
deficit hyperact disord schizophrenia neuropath pain complet
initi phase studi expect report phase target engag
biomark studi healthi phase safeti pk data early-stag
huntington diseas
pleas see import disclosur inform page report
pleas see import disclosur inform page report
brexanolon pipelin tabl areadrugmoaformulationindicationstagemilestonecorp partnerpartn rightszulresso brexanolon gabaivpostpartum depress sever marketedproduct launch expect june fda approv march depress moder phase report posit phase top-line data jan depress disord mdd phase mountain phase data expect dose commenc dec co-morbid insomnia polysomnographi sleep studi phase rainforest phase data sleep studi expect studi retreat treatment-fre intervi phase open-label shorelin phase data expect studi monotherapi without antidepress phase studi potenti start depressionphas ii open-label archway phase ii top-line result expect iidiscuss fda next stepssad/mad studyphas iphas mad data expect complet phase sad studi -- essenti tremorphas iphas top-line data expect disord seizur phase iongo -- parkinson sphase iongo -- sad/mad studyphas iphas sad/mad data expect hypofunct huntington diseasephas iphas cohort data expect portfolio includ preclin gaba-a receptor posit alloster modul focu acut chronic disordersmdd japan taiwan south exhibit newsflow
pleas see import disclosur inform page report
timingexpect newsflowdrug issu interim final rule control drug within day ii open-label part data archway bipolar depress target engag data healthi commerci launch zulresso cohort data cohort data essenti mad data file strategi ema zulresso feedback fda sleep disord phase mainten studi mdd file zulresso data mdd polysomnographi data mdd co-morbid insomnia open-label data retreat mdd patient long-term retreat data mdd patient equiti research
pleas see import disclosur inform page report
 depress franchis could gener ww sale time zulresso mdd mdd mdd comorbid insomnia brexanolon postpartum depress
brexanolon iv intraven use approv fda march
known chemic ident endogen allopregnanolon drug
administ singl iv infus hour
allopregnanolon highli potent posit alloster modul -aminobutyric-
brexanolon enhanc inhibit brain restor dysregul neural
activ neg mood reduc symptom
brexanolon clinic program consist three random placebo-control
studi moderate/sever
brexanolon mechan action moa
brexanolon inhibit neg mood symptom modul gaba-a receptor
brain
brexanolon chemic ident allopregnanolon natur occur
by-product human hormon progesteron
allopregnanolon highli potent posit alloster modul -aminobutyric-
alloster modul bind receptor site distinct activ site induc
conform chang receptor alter receptor affin
endogen ligand mean enhanc activ neurotransmitt
gaba site distinct benzodiazepin xanax valium
posit alloster modul increas affin gabaa receptor
chief inhibitori neurotransmitt brain gaba block nerv impuls
promot relax balanc mood allevi pain
enhanc gaba-a bind lead inhibitori effect neurotransmiss reduc
chanc patient experienc neg effect conscious
licens materi research allopregnanolon univers
california late compani secur exclus licens agreement
ligand pharma subsidiari cydex sep leverag ligand captisol
technolog make allopregnanolon water-solubl essenc brexanolon
allopregnanolon formul captisol iv use
allopregnanolon fluctuat play role neuropsychiatr condit
mdd
allopregnanolon allo naturally-occur metabolit by-product progesteron
produc increas amount matern fetal brain pregnanc
gener allo promot child develop offer neuroprotect benefit fetus
howev allo level brain decreas substanti mother give
birth fluctuat trigger anxieti depress neg symptom
schizophrenia among mood
exhibit fluctuat during/
pleas see import disclosur inform page report
mood disord affect mother within first
month childbirth mother suffer debilit symptom interfer
daili function develop suicid behavior would burden
mother also child famili unit believ mood disord draw
case per year us alon though estim vari wide among clinic
studi largest risk factor associ histori depress
symptom anxieti suicid ideat depress mood dysphoria loss interest
pleasur anhedonia chang appetit sleep disturb insomnia fatigu
cognit dysfunct deficit attent concentr memori
sever ill determin nine-item patient health questionnair
mild/moder pdd character depress symptom score
sever includ symptom score point
treatment approv treatment brexanolon
case handl outpati basi psychotherapi mild/moder
ssri antidepress moderate/sever first-lin treatment
issu antidepress agent typic delay late onset
action take week achiev posit respons requir chronic
dose achiev outcom uniformli effect may requir multipl
agent addit mother may concern effect antidepress
 ssri bupropion mirtazapin neurolog develop infant sinc
antidepress medic secret breast milk
brexanolon altern allopregnanolon shown clinic evid treat
patient gabaa modul brexanolon chemic
ident endogen allo could provid safe altern
pleas see import disclosur inform page report
etiologysymptomsprevalencetreatmentsmechanist rationaleallopregnanolon reproduct hormon decreas rapidli birthextrem sad hopeless suicid ideat anxieti fatigueaffect mother within first year birthcommonli use treatment includ ssri snrisdysfunct gaba signal due hormon chang exhibit breakdown pdd sever preval vari studi region/countri
hamilton rate scale depress
mdd studi gener describ treatment outcom use term respons
remiss deriv amount improv patient achiev ham-
respons improv percent less threshold remiss
remiss depress rate scale score less equal specif cutoff
defin normal rang point
exhibit hamilton rate scale depress
pleas see import disclosur inform page report
region/compani mild moder moder sever sever psychiatri perinat neonat nur volume number pacif journal tropic medicin lancet estim patient moder sever management assess base variou literatur includ sever equiti research
market model suggest brexanolon sale
built incid model use top-down approach forecast us eu
revenu brexanolon assum ww peak sale
includ royalti incorpor probability-adjust dcf specif
model us sale roughli ex-u royalti note
model predic assumpt patent eventu issu
provid exclus toth model patent expiri
annual incid new patient us eu region
 pregnant mother
start diagnosi rate sinc research show stigma associ
matern psychiatr ill deter mother seek treatment
believ diagnosi rate increas time driven increas
awar among doctor potenti approv around
could offer even safer altern caus loss consciousness/
faint potenti approv ganaxolon
believ moder sever popul repres
patient respect assumpt chime detail provid
doctor note patient consid sever
conserv penetr mild/moder doctor
anticip use popul
potenti eu partnership approval/launch
penetr outer year less us
eu account conserv view cannib
competit iv-to-or dose formul per doctor check
howev believ portion sever market may better serv
brexanolon vs provid faster/deep onset relief particular
start price us eu respect
expect partner market drug eu possibl japan potenti
pay royalti revenu low double-digit percentag
downsid scenario assum multipl peak sale
base case assum multipl peak sale
upsid scenario assum multipl peak sale
scenario support dcf valuat
pleas see import disclosur inform page report
exhibit zulresso brexanolon market model pdd
pleas see import disclosur inform page report
brexanolon model analysi postpartum depress chang assumpt bluebrexanolon sale summari total sale brexanolon patient total patients- brexanolon postpartum depress us market popul annual growth live total incid total diagnos diagnosi mild epd score moder edp score sever edp score total brexanolon patient treated- mild moder sever annual gross price annual net price- gross us revenu revenu mild- revenu moderate- revenu severe- reported/project incom statement- brexanolon postpartum depress eu market popul annual growth live birth total incid total diagnos diagnosi mild epd moder edp sever edp total brexanolon patient treated- mild moder sever annual gross price annual net price- gross revenu royalti royalti equiti research
brexanolon achiev rapid meaning benefit patient
expect launch commerci june brexanolon zulresso first
therapi indic specif post-partum depress treatment brexanolon
safeti efficaci establish three placebo-control random double-blind
studi includ one phase ii trial two phase studi studi show
singl infus brexanolon iv provid rapid clinic meaning
stat sig benefit reduc depress symptom
brexanolon iv administ continu infus
recommend maximum dose
dose schema requir multipl bag titrat four hour follow
hour hour mainten hour hour
taper hour
studi use ham-d rate scale primari endpoint hour
studi phase ii trial sever baselin
studi phase trial sever hummingbird studi
studi phase trial moder ham-d humminbird studi
control phase studi brexanolon iv hummingbird moderate/sever
patient studi enrol sever patient studi enrol moder
studi brexanolon iv dose achiev primari endpoint show
statistically-signific reduct hour versu placebo
pleas see import disclosur inform page report
phase sever trial saw benefit depress score
patient random receiv g/kg/hr g/kg/hr placebo
baselin score point across three arm
score reduct reduct observ earli
hour day primari endpoint hour ug/kg dose show
reduct baselin vs placebo point delta ug/kg
dose show reduct vs placebo point delta effect
maintain follow-up period stat sig
pleas see import disclosur inform page report
respons rate reduct baselin gener mid-dos
high dose vs pbo hour hour day
exhibit respons rate time sever patient
remiss rate score normal statu gener mid-
dose high dose vs pbo hour hour day
exhibit remiss rate time sever patient
pleas see import disclosur inform page report
phase moder trial saw point benefit depress score
patient random receiv g/kg/hr placebo baselin ham-
score point arm
score reduct reduct observ earli
hour day primari endpoint hour ug/kg dose show
reduct baselin vs placebo point delta even though
placebo arm show larger benefit day effect gener maintain
throughout follow-up period
respons rate reduct baselin gener
brexanolon vs pbo hour hour even though respons
higher placebo arm day pbo vs believ
continu show durabl effect day
pleas see import disclosur inform page report
exhibit repons rate time moder patient
remiss rate score normal statu gener
brexanolon vs pbo hour hour even though remiss
higher placebo arm day pbo vs believ
continu show durabl effect day
exhibit remiss rate time moder patient
pleas see import disclosur inform page report
fda adcom panel fda identifi loss conscious
loc concern safeti issu brexanolon loc event prompt
fda requir util risk evalu mitig strategi rem therebi
ensur administr brexanolon approv would administ
implic rem strategi could significantli limit patient access uptak
brexanolon zulresso
statist believ women admit inpati
treatment meet hospit admiss criteria
brexanolon patient experienc loc syncop faint presyncop
infus
one patient faint blood draw fear needl
one patient presyncop lightheaded vertigo stand
resolv sit
four patient fell asleep suddenli two experienc pump malfunct
loc abrupt case
loc event resolv dose interrupt
brexanolon safeti data phase ii/iii studi
one fda conclus brexanolon safeti known way
fda note observ relationship loc brexanolon dose
blood level time drug well measur age vital sign
fda believ monitoring/intervent rem requir given loc risk
affect patient fall infant drop smother
safeti concern led rem restrict like limit patient
healthcar profession hcp oversight monitor loss conscious
loc parti agre hcp need on-site overse administr
brexanolon includ monitor infus durat monitor
excess sedat hcp dose adjust interrupt treatment case
excess sedat he/sh immedi stop treatment case loc
treatment restart
rem patient strategi parti agre brexanolon restrict
rem inform risk excess sedat post-approv set
pleas see import disclosur inform page report
restrict distribut certifi healthcar set maintain registri
gather patient inform includ medic histori concomit medic
treatment home set fda open discuss strategi
administr brexanolon safe home set
note oral shown syncope/ loss conscious phase
studi phase ii mdd studi approv patient could take home
could drive patient uptak significantli section
pleas see import disclosur inform page report
postpartum depress major
major depress disord mdd highli disabl highli preval potenti
life-threaten condit patient histori mania undergo least two
week major depress episod symptom includ depress mood loss
interest/enjoy insomnia low energi chang appetit patient suffer
anxieti well moderate/sever mdd patient gener carri
statist current treatment
major depress rank second us among diseases/injuri caus disabl
lifetim preval mdd
estim recurr rate within two year recoveri singl
episod risk recurr within five year
physician tend use combin pharmacotherapi psychotherapi first-
although antidepress wide prescrib patient gener feel effect
week later achiev respons
ssri tricycl
meta-analysi trial patient remiss rate
psychotherapi versu control condit wait list usual care though
meta-analys tend overestim psychotherapi clinic benefit
pleas see import disclosur inform page report
etiologysymptomsprevalencetreatmentsmechanist rationalereduc level allopregnanolon peripher blood cerebrospin fluid depress mood loss interest/enjoy insomnia low energi anxieti chang appetiteaffect adult us recurr rate recoveri year within yearscommonli use treatment includ ssri snri well psychotherapydysfunct gaba signal equiti research
repres linchpin depress program
next-gen oral compound phase studi sever
major depress disord mdd evalu indic
includ bipolar depress insomnia similar brexanolon ganaxolon
posit alloster modul gabaa receptor target synapt
extrasynapt gabaa receptor import show episod
faint loss conscious across mdd patient major safeti
differenti brexanolon could ultim drive signific market uptak
exhibit clinic develop path depress
june fda agre expedit develop plan pdd/mdd
requir complet three pivot studi file nda
complet placebo-control phase pdd studi robin deem pivot
complet placebo-control phase ii mdd studi also deem pivot
on-going placebo-control phase mdd studi mountain
data expect studi evalu dose
mdd patient four week addit follow-up
conduct three addit mdd studi could help solidifi
safeti profil enhanc drug commerci valu label expans
could includ nda packag expect file
estim although three aforement studi alreadi meet nda file
requir assum mountain studi posit opt complet
three addit phase mdd studi file fda establish
long-term safeti optim commerci valu notabl compani
expect three studi prolong mdd program suggest
eventu nda packag could compris six phase pivot studi five placebo-
placebo-control phase monotherapi studi goal
keep patient symptom-fre mainten studi expect studi start
immin expect data read
shorelin open-label phase retreat studi patient whose
symptom recur as-need therapi expect report data
pleas see import disclosur inform page report
rainforest placebo-control phase polysomnographi trial
sleep studi mdd patient co-morbid insomnia expect report data
benefit efficaci instanc loss consciousness/faint
jan report placebo-control top-line phase result sever
patient take daili dose vs placebo posit data cement
idea work like brexanolon zulresso iv delta depress
score similar iv data question whether repeat mdd
biolog allopregnanolon could differ mdd phase ii mdd data
may fluke
phase data show statist signific reduct depress
symptom compar placebo includ rapid onset effect start day
persist day end treatment maintain four week
note patient treat two week outpati set
clinic effect size look similar brexanolon studi
demonstr point benefit placebo ham-d depress score variou
score reduct reduct show vs pbo day
vs pbo week vs pbo week
respons rate reduct baselin two week treatment
four-week follow-up week compar placebo
respect impli pbo-adj rate week week
remiss rate score normal statu two week
treatment four-week follow-up week compar
placebo respect impli pbo-adj rate week week
secondari endpoint madr hama-a cgi-i statist signific trend
consist primari endpoint
safeti summari loss conscious syncop either arm trial
overal vs pbo
common somnol drug vs pbo headach vs
hyperhidrosi vs
one patient experienc sae resolv dose reduct
anoth placebo patient experienc sae
one patient discontinu due ae
pleas see import disclosur inform page report
exhibit achiev similar benefit brexanolon across variou timepoint
complet phase iib mdd studi show profound efficaci
remiss rate loss conscious faint
dec report double-blind placebo-control pivot phase ii data
moderate/sever mdd patient enabl compani start phase
mountain studi follow year treatment oral show
statist signific greater reduct depress symptom versu placebo ham-
variou timepoint primari endpoint evalu score reduct
day dose administ night food
achiev rapid onset effect day week
maintain end follow-up week day
patient femal men random receiv
capsul match placebo
baselin score least point moderate/sever
score reduct stat-sig mean reduct observ follow
first dose day maintain end treatment day week vs
pleas see import disclosur inform page report
pbo point delta day vs pbo point delta week
vs pbo point delta week stat-sig
exhibit administr lead signific day
sustain reduct depress symptom men women phase ii
remiss rate score normal statu day week
week compar placebo respect impli
pbo-adjust rate day stat sig week stat sig week
stat sig
secondari endpoint madr hama-a cgi-i stat sig day
exhibit remiss rate phase ii studi moderate/sever mdd
pleas see import disclosur inform page report
